卡度尼利单抗不良反应临床特点分析
Analysis of the clinical characteristics of adverse reactions associated with cadonilimab
李金兰 1潘勇 1曾媚姿 1陈珊珊1
作者信息
- 1. 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院药学部,长沙 410013
- 折叠
摘要
目的:分析卡度尼利单抗所致不良反应(adverse drug reaction,ADR)的发生情况及临床特点,为临床合理用药提供参考.方法:对2021年1月-2022年12月我院应用卡度尼利单抗发生ADR的18例住院患者病例资料进行回顾性分析.结果:18例发生卡度尼利单抗相关ADR中,男性12例(66.67％),女性6例(33.33％),中位发病年龄为64岁,原发疾病以肺癌为主(14例,77.78％).临床主要表现为皮疹瘙痒、免疫相关甲状腺功能异常、免疫相关垂体炎、免疫相关心肌炎等.免疫相关肝炎和甲状腺功能减退ADR的中位发生时间分别为11和12周,免疫相关肺炎中位发生时间为给药19.7周,脑炎中位发生时间为43.3周,心肌炎和垂体炎的中位发生时间为30周左右,皮肤毒性的中位时间为6.1周.所有的ADR经对症支持治疗后症状治愈或好转,无不良事件相关死亡病例.结论:在临床合理使用卡度尼利单抗时,应提高临床工作者卡度尼利单抗ADR的监测,保障患者安全有效用药.
Abstract
Objective:To analyze the incidence and clinical characteristics of adverse drug reactions(ADRs)caused by cardinirimab,so as to provide reference for clinical rational drug use.Methods:From January 2021 to December 2022,the medical records of 18 inpatients with ADRs caused by cardonirimab in our hospital were retrospectively analyzed.Results:Among the 18 cases of cardonirimab-related ADRs,12 were males(66.67％),6 were females(33.33％),the median age of onset was 64 years,and the primary disease was lung cancer(14 cases,77.78％).The main clinical manifestations were rash and itching,immune-related thyroid dysfunction,immune-related hypophysitis,and immune-related myocarditis.The median occurrence time of immune-related hepatitis and hypothyroidism ADRs were 11 weeks and 12 weeks respectively,the median occurrence time of immune-related pneumonia was 19.7 weeks after administration,and the median occurrence time of encephalitis was 43.3 weeks;the median occurrence time of myocarditis and hypophysitis was about 30 weeks;the median time of skin toxicity was 6.1 weeks.All ADRs were cured or improved after symptomatic and supportive treatment,and there was no death related to adverse events.Conclusion:When using cardonirimab in clinical practice,it is necessary to strengthen the monitoring of ADRs to ensure the safe and effective drug use.
关键词
卡度尼利单抗/不良反应/程序性细胞死亡蛋白1/细胞毒性T淋巴细胞相关抗原4/临床特点Key words
cadonilimab/adverse reactions/programmed cell deathreceptor-1/cytotoxic T-lymphocyte-associated protein-4 inhibitor/clinical features引用本文复制引用
出版年
2024
NETL
NSTL
万方数据